Mendus AB (1YG0)

Overview

Mendus AB (publ) is a biopharmaceutical company engaged in the research, development, and potential commercialization of innovative immunotherapies and relapse vaccines for various forms of cancer. Originating as Immunicum AB (publ), the company undertook a rebranding to Mendus AB (publ) in June 2022, signaling a new phase in its operational strategy. Established in 2002 and based in Stockholm, Sweden, Mendus has carved out a significant niche in the immuno-oncology landscape through a focus on leveraging the body's immune system to fight malignancies. Collaboration forms a cornerstone of its research ethos, with partnerships spanning entities like PCI Biotech Holding ASA, the Icahn School of Medicine at Mount Sinai, and the AUstralasian Leukaemia and Lymphoma Group, aiming to broaden the scope and accelerate the development of its therapeutic candidates.

Products and Services

DCP-001 - Leading Mendus AB's pipeline is DCP-001, currently explored in advanced clinical trials for its efficacy against acute myeloid leukemia (Phase II ADVANCE-II trial) and ovarian cancers (Phase I ALISON trial). This candidate signifies the company's commitment to targeting some of the most challenging cancers, focusing on innovative vaccine-based approaches to stimulate patients' immune responses.

Ilixadencel - Another significant product, Ilixadencel, is undergoing Phase II clinical trials to evaluate its effectiveness in treating kidney cancer and gastrointestinal stromal tumors. Highlighting Mendus AB's expertise in immuno-oncology, Ilixadencel represents a promising therapeutic approach aimed at enhancing the immune system's ability to recognize and destroy cancer cells.

Research Collaborations - Beyond its in-house pipeline, Mendus AB (publ) actively engages in collaborative research efforts, including a novel cancer vaccination treatment project with PCI Biotech Holding ASA and a clinical research partnership with the Icahn School of Medicine at Mount Sinai. Additionally, the company is working with the Australasian Leukaemia and Lymphoma Group to expand clinical testing of vididencel as a maintenance therapy for acute myeloid leukemia (AML), emphasizing its open approach to innovation and the advancement of cancer treatments through strategic partnerships.